-
-
Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study
-
-
Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
-
-
The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
-
-
Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study
-
-
5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
-
-
THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS
-
-
Long-term Radiographic Outcome in Psoriatic Arthritis Patients Treated with Golimumab: 104 Week Results from the GO-REVEAL Study
-
-
Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial
-
-
LONG-TERM RADIOGRAPHIC OUTCOME IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GOLIMUMAB: 104 WEEK RESULTS FROM THE GO-REVEAL STUDY
-
-
Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al Reply
-
-
The Effect of Anti-Tumor Necrosis Factor Therapy with Two Different Doses of Golimumab on Radiographic Progression in Definite Ankylosing Spondylitis: 4-Year Results
-
-
Sustained Clinical Response with Golimumab Administered Subcutaneously Every 4 Weeks in Ankylosing Spondylitis: 104-Week Results of a Randomized, Placebo-Controlled Study
-
-
The Effects of Golimumab on Radiographic Progression in Rheumatoid Arthritis Results of Randomized Controlled Studies of Golimumab Before Methotrexate Therapy and Golimumab After Methotrexate Therapy
-
-
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
-
-
GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES
-
-
GOLIMUMAB, A NEW, HUMAN, TNF-ALPHA ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS: 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBOCONTROLLED GO-RAISE STUDY
-
-
GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY
-
-
Golimumab Inhibits Progression of Radiographic Damage in Patients with Psoriatic Arthritis: 52 Week Results From the GO-REVEAL Study
-
-
Golimumab, a New, Human, TNF-alpha Antibody Administered Subcutaneously Every 4 Weeks, in Ankylosing Spondylitis: 104-Week Efficacy and Safety Results of the Randomized, Placebo-Controlled GO-RAISE Study